Claims for Patent: 8,563,008

Summary for Patent: 8,563,008

Title:	Polynucleotides and polypeptides involved in gestational malaria, and biological applications
Abstract:	The disclosure provides novel antigens involved in gestational malaria, and more particularly to polynucleotide and polypeptide sequences, conjugates, cloning vectors including the sequences for the preparation of immunogenic compositions and vaccines, antibodies, and to their for treating gestational malaria. Diagnostic methods and kits are described.
Inventor(s):	Deloron; Philippe Lucien (Paris, FR), Tuikue Ndam; Nicaise George (Paris, FR), Bertin; Gwladys Irenee (Neuilly Plaisance, FR), David; Peter (Paris, FR), Bischoff; Emmanuel (Boulogne-Billancourt, FR), Proux; Caroline Stephanie (Montigny le Bretonneux, FR), Coppee; Jean-Yves (Paris, FR), Salanti; Ali (Broenshoj, DK), Lavstsen; Thomas (Hoersholm, DK)
Assignee:	Institut de Recherche pour le Development (IRD) (Marseille Cedex, FR) Institut Pasteur (Paris, FR)
Application Number:	12/450,874
Patent Claims:	1. An isolated or purified polypeptide encoded by the polynucleotide consisting of SEQ ID NO. 3 2. A recombinant polypeptide encoded by the polynucleotide consisting of SEQ ID NO:3. 3. A medicament comprising a polypeptide of claim 1. 4. A conjugate comprising a carrier and a polypeptide wherein the polypeptide is encoded by the polynucleotide consisting of SEQ ID NO:3. 5. A composition comprising the conjugate of claim 4 and a vehicle. 6. An immunogenic composition comprising a polypeptide of claim 1, in combination with a pharmaceutically acceptable vehicle. 7. The immunogenic composition of claim 6, further comprising at least one P. falciparum antigen chosen from var2csa, pre-erythrocytic stage antigens, and asexual or sexual erythrocytic stage antigens. 8. The conjugate of claim 4 wherein the carrier is a physiologically acceptable, nontoxic, natural or synthetic carrier. 9. The conjugate of claim 4 wherein the carrier is selected from the group consisting of a viral particle, a lipid, a polylysine, a poly (DL-alanine)-poly(-lysine), nitrocellulose, polystyrene, a microparticle, a biodegradable polymer, an outer membrane protein complex of Neisseria meningitides, bovine serum albumin, tetanus toxoid, ovalbumin, keyhole limpet hemocyanin, bovine thyroglobulin, a HbSAg from hepatitis B virus, a HBcAg from hepatitis B virus, a rotavirus capsid protein, a human papilloma virus L1 protein, type 6, 11 and 16 virus-like particles, and a tuberculin purified protein derivative. 10. The conjugate of claim 9 wherein the carrier is selected from the group consisting of a latex bead microparticle and a polyphosphoglycan microparticle.

Details for Patent 8,563,008

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Par Pharmaceutical Companies, Inc.	APLISOL	tuberculin, purified protein derivative	Injection	103782	04/20/1998		2027-04-17
Sanofi Pasteur Limited	TUBERSOL	tuberculin, purified protein derivative	Injection	103941	02/24/2000		2027-04-17